214286-61-0

Basic information

• Product Name: (1'R,3R,5S)-5-(1'-bromo-2'-methylpropyl)-3-(4''-fluorobenzyl)dihydrofuran-2-one
• Synonyms: (1'R,3R,5S)-5-(1'-bromo-2'-methylpropyl)-3-(4''-fluorobenzyl)dihydrofuran-2-one
• CAS NO: 214286-61-0
• Molecular Weight: 329.209
• Mol File: 214286-61-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1'R,3R,5S)-5-(1'-bromo-2'-methylpropyl)-3-(4''-fluorobenzyl)dihydrofuran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (1'R,3R,5S)-5-(1'-bromo-2'-methylpropyl)-3-(4''-fluorobenzyl)dihydrofuran-2-one(214286-61-0)
• EPA Substance Registry System: (1'R,3R,5S)-5-(1'-bromo-2'-methylpropyl)-3-(4''-fluorobenzyl)dihydrofuran-2-one(214286-61-0)

Safety Data

• Hazardous Substances Data: 214286-61-0(Hazardous Substances Data)

Upstream product

• 61229-07-0 trans-6-methylhept-4-enoic acid 
• 214286-38-1 trans-(1'R,2'R)-6-methylhept-4-enoic acid (2'-hydroxy-1'-methyl-2-phenylethyl)methyl amide 
• 179617-47-1 trans-6-methyl-hept-4-enoic acid ethyl ester 
• 112375-59-4 trans-6-methylhept-4-enoic acid chloride 
• 214286-60-9 trans-(1'R,2S,2'R)-6-methyl-2-(4''-fluorobenzyl)hept-4-enoic acid (2'-hydroxy-1'-methyl-2-phenylethyl)methyl amide 

Downstream Products

• 214286-70-1 ethyl-3--L-Phe(4-F)-L-(Tr-Gln)>-E-propenoate 
• 214286-66-5 ethyl-3--L-Phe(4-F)-L-(Tr-Gln)>-E-propenoate 
• 223526-67-8 (2R,5S)-5-(tert-butoxycarbonylamino)-2-(4-fluorobenzyl)-6-methyl-4-oxoheptanic acid 
• 214286-64-3 (1S,2'S,4'S)-<2-methyl-1-<4'-(4''-fluorobenzyl)-5'-oxo-tetrahydrofuran-2'-yl>propyl>carbamic acid tert-butyl ester 
• 214286-62-1 (1'S,3R,5S)-5-(1'-azido-2'-methylpropyl)-3-(4''-fluorobenzyl)dihydrofuran-2-one 

Relevant articles and documents

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics

The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an e